Articles from Vanqua Bio

CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, taking place in Copenhagen, Denmark on March 17-21.

CHICAGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced positive interim results from the Phase 1b portion of its clinical trial of VQ-101, an orally administered, fully brain-penetrant, allosteric activator of GCase. The Phase 1b portion of the study is evaluating safety, pharmacokinetics, and pharmacodynamics across multiple ascending doses in Parkinson’s patients with and without GBA mutations.

CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming scientific conferences – the GBA1 Meeting 2025, which will take place in Montreal, Canada June 5-7, 2025 and the European Academy of Neurology, taking place in Helsinki, Finland June 21-24, 2025.

CHICAGO, March 27, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, taking place in Vienna, Austria on April 1-5.

CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, which will be held in Boston on December 10 – 12.

CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced positive results from its Phase 1 clinical trial of VQ-101, an orally administered, brain-penetrant, allosteric activator of GCase. The Phase 1a portion of the study evaluated safety, pharmacokinetics, and pharmacodynamics across single and multiple ascending doses in healthy volunteers.

CHICAGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate in the following scientific conferences:

CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate in the inaugural GBA1 meeting which will bring together health professionals and stakeholders from both academia and industry engaged in GBA1 research. The meeting will take place from June 27 - 29, 2024, at The Montreal Neurological Institute-Hospital. It is sponsored by Cure Parkinson’s, The Michael J. Fox Foundation, Parkinson Canada, The Silverstein Foundation, and the Hilary & Galen Weston Foundation.

- VQ-101 is a potent allosteric activator of glucocerebrosidase (GCase)- The Phase 1 program aims to demonstrate VQ-101’s pharmacodynamic effects in healthy volunteers and Parkinson’s patients

CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that the company will participate in the Stifel 2024 CNS Days Conference, which is being held virtually March 19-20. The company will present data on its lead program targeting glucocerebrosidase (GCase) as a potential treatment for Parkinson’s disease.

Posters to be presented at the AD/PD™ 2024 Conference

CHICAGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase (GCase), will enter clinical development in the first quarter of 2024, with an initial indication in Parkinson’s disease (PD). To support the company’s clinical evolution, Vanqua Bio also announced the appointment of three executives to leadership roles: Jesse Cedarbaum, MD and Omer Siddiqui have joined the company as Chief Medical Officer and Chief Development Officer, respectively, and Rand Sutherland, MD, MPH has joined the Board of Directors.

CHICAGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative diseases, announced today that the company will participate in the Leerink Partners Biopharma Private Company Connect, which is being held virtually October 25-26.

CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative diseases, announced today that the company will participate in the Stifel 2023 CNS Day Conference, which is being held virtually March 28-29.